{"id":966,"date":"2004-05-01T12:01:00","date_gmt":"2004-05-01T10:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/osteoporose-therapie-stand-2004"},"modified":"2022-03-17T14:10:38","modified_gmt":"2022-03-17T13:10:38","slug":"osteoporose-therapie-stand-2004","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/osteoporose-therapie-stand-2004","title":{"rendered":"Osteoporose-Therapie &#8211; Stand 2004"},"content":{"rendered":"<p>Zusammenfassung: Die Pharmakotherapie der Osteoporose ist in den letzten zehn Jahren \u00fcbersichtlicher geworden. Neben der Basistherapie mit Kalzium und Vitamin D3 haben sich Bisphosphonate in randomisierten kontrollierten Studien als wirksam erwiesen, Frakturen zu verhindern. Die sogenannte Hormonersatz-Therapie ist wegen ihrer UAW als generelle Sekund\u00e4rpr\u00e4vention der Osteoporose f\u00fcr Frauen in der Postmenopause nicht mehr zu empfehlen. [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Die Pharmakotherapie der Osteoporose ist in den letzten zehn Jahren \u00fcbersichtlicher geworden. Neben der Basistherapie mit Kalzium und Vitamin D3 haben sich Bisphosphonate in randomisierten kontrollierten Studien als wirksam erwiesen, Frakturen zu verhindern. Die sogenannte Hormonersatz-Therapie ist wegen ihrer UAW als generelle Sekund\u00e4rpr\u00e4vention der Osteoporose f\u00fcr Frauen in der Postmenopause nicht mehr zu empfehlen. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[386,2469,145,2468,167,164,57,2467,1102,1105,169,2470,70,66,551,2471,2466,1100,1099,1096,159],"class_list":["post-966","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-alendronat","tag-anabolika","tag-bisphosphonate","tag-calcitonin","tag-cholecalciferol","tag-colecalciferol","tag-estrogene-gestagene","tag-etidronat","tag-fit-studie","tag-hip-studie","tag-kalzium","tag-more-studie","tag-osteoporose","tag-oestrogene-gestagene","tag-parathormon","tag-proof-studie","tag-raloxifen","tag-risedronat","tag-risedronsaeure","tag-vert-studie","tag-vitamin-d"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=966"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/966\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}